Sex differences in atrial fibrillation in India: Insights from the Kerala-AF registry
- PMID: 39817011
- PMCID: PMC11730713
- DOI: 10.1002/joa3.13195
Sex differences in atrial fibrillation in India: Insights from the Kerala-AF registry
Abstract
Background: Much data informing sex differences in atrial fibrillation (AF) comes from Western cohorts. In this analysis, we describe sex differences in Kerala, India, using the Kerala-AF registry-the largest AF registry from the Indian subcontinent.
Methods: Patients aged ≥18 years were recruited from 53 hospitals across Kerala. Patients were compared for demographics, treatments, and 12-month outcomes, including major adverse cardiovascular events (MACE) and bleeding.
Results: Male patients were more likely to have a smoking and/or alcohol history and had more ischaemic heart disease (46.2% vs. 25.5%; p < 0.001). Female patients had more valvular AF (35.1% vs. 18.0%; p < 0.001), and more use of calcium-channel blockers (23.3% vs. 16.5%; p < 0.001) or digoxin (39.6% vs. 28.5%; p < 0.001). Almost one in four patients were not anticoagulated despite raised CHA2DS2-VASc scores. 12-month MACE outcomes did not differ by sex (male: 30.2% vs. female: 29.4%; p = 0.685), though bleeding events were more common in male patients (2.4% vs. 1.3%; p = -0.038), driven by minor bleeding (1.2% vs. 0.5%).
Conclusion: In this large AF cohort from India, male patients had a higher prevalence of ischaemic heart disease, smoking, and alcohol use, while female patients had a higher prevalence of valvular heart disease. MACE did not differ by sex, though bleeding was more common in males. Almost a quarter of patients were not anticoagulated despite raised thromboembolic risk.
Keywords: India; Kerala; South Asia; atrial fibrillation; sex differences.
© 2024 The Author(s). Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of Japanese Heart Rhythm Society.
Conflict of interest statement
GYHL reports: Consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Daiichi‐Sankyo, Anthos. No fees are received personally. GYHL is a National Institute for Health and Care Research (NIHR) Senior Investigator and co‐principal investigator of the AFFIRMO project on multimorbidity in AF, which has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 899871. DG reports: Speaker for Boehringer Ingelheim, Biosense Webster, and Boston Scientific. Proctor for Abbott. Research Grants from Medtronic, Biosense Webster and Boston Scientific. The other authors report no conflicts of interest.
References
-
- Charantharayil Gopalan B, Namboodiri N, Abdullakutty J, Lip GY, Koshy AG, Krishnan Nair V, et al. Kerala atrial fibrillation registry: a prospective observational study on clinical characteristics, treatment pattern and outcome of atrial fibrillation in Kerala, India, cohort profile. BMJ Open. 2019;9:e025901. 10.1136/bmjopen-2018-025901 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources